A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
← catalyst calendarNCT06456580 · readout ≤ 284 d
Sponsored by Vor Biopharma (industry) · VOR — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
180estimated
Sites
111
Countries
Argentina, Australia, Belgium +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-17 | actual | When the study began enrolling |
| Primary completion | May 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Generalized Myasthenia Gravis
Interventions
- Biological: Telitacicept — also filed as RC18, RC18-L
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Week 24
measured Week 24
Permalink · VOR's whole pipeline · Catalyst calendar · Every registered study · What changed